Chan KW, Smeijer JD, Schechter M, Jongs N, et al. Post-hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease. Kidney Int 2023 Aug 30:S0085-2538(23)00610-5. doi: 10.1016/j.kint.2023.
PMID: 37657768